Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma

Recently, immunotherapy has yielded promising results in several cancer types. Contrary to the established classical chemotherapy‐dosing paradigm, a maximum tolerated dose approach does not always produce better clinical outcomes for novel targeted therapies, as their efficacy is frequently robust a...

Descripción completa

Detalles Bibliográficos
Autores principales: de Greef, R, Elassaiss‐Schaap, J, Chatterjee, M, Turner, DC, Ahamadi, M, Forman, M, Cutler, D, de Alwis, DP, Kondic, A, Stone, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270292/
https://www.ncbi.nlm.nih.gov/pubmed/27653180
http://dx.doi.org/10.1002/psp4.12131
_version_ 1782501161817866240
author de Greef, R
Elassaiss‐Schaap, J
Chatterjee, M
Turner, DC
Ahamadi, M
Forman, M
Cutler, D
de Alwis, DP
Kondic, A
Stone, J
author_facet de Greef, R
Elassaiss‐Schaap, J
Chatterjee, M
Turner, DC
Ahamadi, M
Forman, M
Cutler, D
de Alwis, DP
Kondic, A
Stone, J
author_sort de Greef, R
collection PubMed
description Recently, immunotherapy has yielded promising results in several cancer types. Contrary to the established classical chemotherapy‐dosing paradigm, a maximum tolerated dose approach does not always produce better clinical outcomes for novel targeted therapies, as their efficacy is frequently robust at pharmacologically active doses below the maximum tolerated dose. Integrated safety and efficacy assessments are needed to inform clinical dose and trial design, and to support an early identification of potentially safe and efficacious combination treatments.
format Online
Article
Text
id pubmed-5270292
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-52702922017-02-01 Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma de Greef, R Elassaiss‐Schaap, J Chatterjee, M Turner, DC Ahamadi, M Forman, M Cutler, D de Alwis, DP Kondic, A Stone, J CPT Pharmacometrics Syst Pharmacol Perspective Recently, immunotherapy has yielded promising results in several cancer types. Contrary to the established classical chemotherapy‐dosing paradigm, a maximum tolerated dose approach does not always produce better clinical outcomes for novel targeted therapies, as their efficacy is frequently robust at pharmacologically active doses below the maximum tolerated dose. Integrated safety and efficacy assessments are needed to inform clinical dose and trial design, and to support an early identification of potentially safe and efficacious combination treatments. John Wiley and Sons Inc. 2016-11-05 2017-01 /pmc/articles/PMC5270292/ /pubmed/27653180 http://dx.doi.org/10.1002/psp4.12131 Text en © 2016 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Perspective
de Greef, R
Elassaiss‐Schaap, J
Chatterjee, M
Turner, DC
Ahamadi, M
Forman, M
Cutler, D
de Alwis, DP
Kondic, A
Stone, J
Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma
title Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma
title_full Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma
title_fullStr Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma
title_full_unstemmed Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma
title_short Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma
title_sort pembrolizumab: role of modeling and simulation in bringing a novel immunotherapy to patients with melanoma
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270292/
https://www.ncbi.nlm.nih.gov/pubmed/27653180
http://dx.doi.org/10.1002/psp4.12131
work_keys_str_mv AT degreefr pembrolizumabroleofmodelingandsimulationinbringinganovelimmunotherapytopatientswithmelanoma
AT elassaissschaapj pembrolizumabroleofmodelingandsimulationinbringinganovelimmunotherapytopatientswithmelanoma
AT chatterjeem pembrolizumabroleofmodelingandsimulationinbringinganovelimmunotherapytopatientswithmelanoma
AT turnerdc pembrolizumabroleofmodelingandsimulationinbringinganovelimmunotherapytopatientswithmelanoma
AT ahamadim pembrolizumabroleofmodelingandsimulationinbringinganovelimmunotherapytopatientswithmelanoma
AT formanm pembrolizumabroleofmodelingandsimulationinbringinganovelimmunotherapytopatientswithmelanoma
AT cutlerd pembrolizumabroleofmodelingandsimulationinbringinganovelimmunotherapytopatientswithmelanoma
AT dealwisdp pembrolizumabroleofmodelingandsimulationinbringinganovelimmunotherapytopatientswithmelanoma
AT kondica pembrolizumabroleofmodelingandsimulationinbringinganovelimmunotherapytopatientswithmelanoma
AT stonej pembrolizumabroleofmodelingandsimulationinbringinganovelimmunotherapytopatientswithmelanoma

Ejemplares similares